Cullinan Therapeutics（纳斯达克股票代码：CGEM）股价下跌 7.6% - 你是否应该卖出？

Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) traded down 7.6% during trading on Tuesday . The company traded as low as $11.43 and last traded at $11.95. 1,110,178 shares traded hands during mid-day trading, an increase of 84% from the average session volume of 602,640 shares. The stock had previously closed at $12.93.

Wall Street Analysts Forecast Growth

CGEM has been the topic of several research reports. Wedbush reaffirmed an "outperform" rating and issued a $25.00 target price on shares of Cullinan Therapeutics in a research report on Thursday, November 20th. Weiss Ratings reissued a "sell (e+)" rating on shares of Cullinan Therapeutics in a research note on Wednesday, October 8th. Morgan Stanley dropped their price objective on Cullinan Therapeutics from $35.00 to $28.00 and set an "overweight" rating on the stock in a report on Monday, August 18th. HC Wainwright raised their price objective on shares of Cullinan Therapeutics from $24.00 to $26.00 and gave the company a "buy" rating in a research report on Thursday, November 20th. Finally, New Street Research set a $26.00 target price on shares of Cullinan Therapeutics in a research note on Thursday. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $27.00.

View Our Latest Report on Cullinan Therapeutics

Cullinan Therapeutics Trading Down 10.5%

The stock has a market capitalization of $683.51 million, a price-to-earnings ratio of -3.50 and a beta of -0.07. The company has a fifty day moving average of $7.47 and a two-hundred day moving average of $7.69.

Cullinan Therapeutics (NASDAQ:CGEM - Get Free Report) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.77) EPS for the quarter, beating analysts' consensus estimates of ($0.95) by $0.18. As a group, sell-side analysts predict that Cullinan Therapeutics, Inc. will post -3.04 earnings per share for the current fiscal year.

Insider Transactions at Cullinan Therapeutics

In related news, major shareholder Lynx1 Capital Management Lp acquired 165,667 shares of the business's stock in a transaction dated Tuesday, October 28th. The stock was acquired at an average price of $8.40 per share, with a total value of $1,391,602.80. Following the completion of the transaction, the insider owned 8,963,500 shares of the company's stock, valued at approximately $75,293,400. This represents a 1.88% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last quarter, insiders have acquired 1,874,057 shares of company stock valued at $13,325,286. Company insiders own 7.16% of the company's stock.

Hedge Funds Weigh In On Cullinan Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Brooklyn Investment Group acquired a new stake in shares of Cullinan Therapeutics during the 1st quarter valued at about $34,000. SG Americas Securities LLC acquired a new position in Cullinan Therapeutics in the third quarter worth about $62,000. Tower Research Capital LLC TRC lifted its stake in Cullinan Therapeutics by 44.6% during the second quarter. Tower Research Capital LLC TRC now owns 8,182 shares of the company's stock worth $62,000 after purchasing an additional 2,523 shares during the period. Inscription Capital LLC acquired a new stake in Cullinan Therapeutics during the third quarter valued at approximately $67,000. Finally, Compass Ion Advisors LLC bought a new stake in shares of Cullinan Therapeutics in the 3rd quarter valued at approximately $82,000. Institutional investors and hedge funds own 86.31% of the company's stock.

Cullinan Therapeutics Company Profile

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.

Featured Articles

• Five stocks we like better than Cullinan Therapeutics
• What Are Earnings Reports?
• A New Leader at Six Flags: Is the Roller Coaster Over?
• Canadian Penny Stocks: Can They Make You Rich?
• 3 Reasons Baidu Could Be the Dark Horse of Global AI
• What is Short Interest? How to Use It
• Betting on the Backbone: 3 AI Infrastructure Stocks

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Cullinan Therapeutics Right Now?

Before you consider Cullinan Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cullinan Therapeutics wasn't on the list.

While Cullinan Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here